[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549999":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":26,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Tang-Du Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with preinvasive lung adenocarcinomas",null,"preinvasive lung adenocarcinomas include atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA)",{"label":13,"type":10,"description":14,"interventionNames":10},"Patients with invasive lung adenocarcinomas","invasive adenocarcinoma(IAC)",[16],{"name":17,"affiliation":18,"role":19},"Cui Guangbin","ang-Du Hospital","STUDY_CHAIR",[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Cui Guangbin, Professor","CONTACT","18992898517","cgbtd@126.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Tangdu Hospital","RECRUITING","Xi'an","Shaanxi","710038","China","CN",{"type":36,"coordinates":37},"Point",[38,39],108.92861,34.25833,{"lat":39,"lon":38},[42,43],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":44,"role":23,"phone":45,"phoneExt":10,"email":46},"Jiang Nan","18093701139","tdfs_jn@163.com",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100549999","differentiating-the-invasiveness-of-lung-adenocarcinoma-by-dual-energy-ct-parameter-100549999",false,"NCT06441357","Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter","Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Using Extracellular Volume Measured in Delay Phase","Inclusion Criteria:\n\n* patients older than 18 years old with pulmonary nodules (diameter≤3 cm).\n* pathologically confirmed as lung adenocarcinoma.\n* without history of other malignancies.\n* accurate hematocrit within 1 week before contrast enhanced dual energy CT examination.\n\nExclusion Criteria:\n\n* with a history of allergy to iodine contrast agents and other reasons who are unable to complete the examination.\n* without histopathology of invasion stage, such as AAH, AIS, MIA and IAC.\n* history of chemotherapy, radiotherapy, or other anti-tumor therapy before contrast enhanced dual energy CT.\n* poor image quality.\n* contrast enhanced dual energy CT scans ≥ 4 weeks before surgery.","ALL","18 Years",{"count":59,"type":60},2000,"ESTIMATED","OBSERVATIONAL","The core purpose of this study is to investigate whether the extracellular volume (ECV) fraction measured in delay phase by dual energy computed tomography (DECT) can distinguish precancerous lesions from early-stage lung adenocarcinomas, which could assist clinical decision making for surgery operation indication and strategy.",[64],"Adenocarcinoma of Lung",[66],"ECV, invasion, lung adenocarcinoma, DECT","2024-05-28",{"date":69,"type":70},"2024-06-04","ACTUAL",{"date":72,"type":60},"2024-06-01",{"date":74,"type":60},"2026-06-30",{"name":5,"class":6},1]